Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Gains from Investment Securities (2018 - 2024)

Historic Gains from Investment Securities for Capricor Therapeutics (CAPR) over the last 10 years, with Q4 2024 value amounting to $1.7 million.

  • Capricor Therapeutics' Gains from Investment Securities changed N/A to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.6 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2024, which is 43705.33% up from last year.
  • According to the latest figures from Q4 2024, Capricor Therapeutics' Gains from Investment Securities is $1.7 million.
  • Capricor Therapeutics' Gains from Investment Securities' 5-year high stood at $10.6 million during Q2 2024, with a 5-year trough of $30421.0 in Q1 2024.
  • Over the past 5 years, Capricor Therapeutics' median Gains from Investment Securities value was $1.8 million (recorded in 2023), while the average stood at $3.3 million.
  • As far as peak fluctuations go, Capricor Therapeutics' Gains from Investment Securities skyrocketed by 160020.77% in 2022, and later tumbled by 9826.83% in 2024.
  • Over the past 5 years, Capricor Therapeutics' Gains from Investment Securities (Quarter) stood at $2.3 million in 2020, then crashed by 97.79% to $51044.0 in 2021, then skyrocketed by 1600.21% to $867854.0 in 2022, then soared by 45.7% to $1.3 million in 2023, then skyrocketed by 31.9% to $1.7 million in 2024.
  • Its last three reported values are $1.7 million in Q4 2024, $10.5 million for Q3 2024, and $10.6 million during Q2 2024.